Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Has Consensus Price Target of $100.86

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $100.86.

TARS has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, October 15th. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak Azamian sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $90.56, for a total value of $905,600.00. Following the transaction, the chief executive officer directly owned 827,991 shares in the company, valued at $74,982,864.96. This trade represents a 1.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William Link, PhD sold 12,500 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total transaction of $979,750.00. Following the sale, the director directly owned 94,487 shares of the company’s stock, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 48,031 shares of company stock valued at $4,004,227. Company insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of TARS. BlackRock Inc. bought a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter worth about $242,705,000. Jupiter Topco LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $176,834,000. Bank of America Corp DE bought a new position in Tarsus Pharmaceuticals in the second quarter worth about $75,099,000. TimesSquare Capital Management LLC acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $23,249,000. Finally, Wasatch Advisors LP acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $23,198,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS opened at $72.64 on Friday. Tarsus Pharmaceuticals has a 12-month low of $53.89 and a 12-month high of $91.53. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -66.64 and a beta of 0.34. The company’s 50-day moving average is $75.17 and its two-hundred day moving average is $67.87. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($12.94). The firm had revenue of $194.57 million for the quarter, compared to analysts’ expectations of $187.83 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. Research analysts expect that Tarsus Pharmaceuticals will post -2.23 EPS for the current year.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter XDEMVY net product sales reached a record $194.6 million, up about 64% year over year and above analyst estimates. The company also said more than one million bottles had been dispensed and cumulative sales since launch had topped $1 billion. Tarsus Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Zacks reported a quarterly loss of $0.78 per share, narrower than its consensus estimate of a $1.43 loss, although the loss was larger than a year earlier. Tarsus Reports Q3 Loss, Tops Revenue Estimates
• Neutral Sentiment: Tarsus appointed Neera Clase as chief commercial officer, a leadership change as the company builds on XDEMVY’s commercial momentum. Tarsus Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Another earnings report characterized the net loss as wider, highlighting continued pressure from expenses and the company’s path to profitability despite sales growth. Tarsus Pharmaceuticals Q3 Net Loss Widens, Revenue Rises

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.